GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
GSK at ESMO 2024
Biomarkers, the unique genetic signature of tumors, help oncologists match patients with the most effective treatment options, transforming cancer care across various tumor types.
Promising Data From Phase II Seasonal Influenza mRNA Vaccine Program
GSK announced positive phase II trial data for its mRNA seasonal flu vaccine, meeting success criteria in younger and older participants. The vaccine showed acceptable safety and reactogenicity. GSK plans to advance to late-stage clinical development. Stock is down 1.52% at $43.10.
GSK's mRNA flu shot is heading to Phase 3; Summit's $235M offering
GSK’s mRNA flu vaccine succeeds against both strains in Phase 2.
GSK mRNA Flu Vaccine Candidate Delivers Favorable Topline Phase 2 Findings, Ready for Phase 3
GSK's phase 2 data for its seasonal influenza mRNA vaccine, GSK4382276A, showed robust immune responses against A and B strains in older and younger adults, supporting progression to phase 3 trials. The vaccine demonstrated acceptable safety and reactogenicity profiles, aiming to develop a best-in-class vaccine for greater protection during flu season.
GSK advances mRNA flu vaccine into phase III trials
GSK's mRNA-based seasonal flu vaccine successfully completed phase II trials, showing positive immune responses and safety profiles, advancing to phase III. The company's full control over development and manufacturing from CureVac, along with AI/ML-based optimizations, strengthens its mRNA vaccine program. GSK's financial stability, with a market cap of $88.32B and a dividend yield of 3.46%, supports ongoing vaccine technology investments.
GSK provides update on phase I/II therapeutic herpes simplex virus (HSV) vaccine trial
GSK's phase II trial of HSV vaccine candidate GSK3943104 did not meet primary efficacy objectives, halting progression to phase III. No safety concerns were observed, and the study will continue for safety monitoring and data collection on recurrent genital herpes.
GSK Stays In mRNA Flu Vaccine Race With Phase II Win
Article sent to my@email.address. All fields required; separate multiple recipients with a semicolon. Active subscribers access full article; others directed to abstract.
© Copyright 2025. All Rights Reserved by MedPath